National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Disease-specific reference case extension: Management of overweight and obesity in adults Methods / process manual consultation NICE process and methods 3 December 2025 Ripretinib for treating ...
The National Institute for Health and Care Excellence

Focusing on what matters most to the NHS

The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...
National Institute for Health and Care Excellence

Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)

NICE is unable to make a recommendation on sarilumab (Kevzara) for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years. This is because the company did not ...
National Institute for Health and Care Excellence

Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults. Lorlatinib is also ...